ClinicalTrials.gg
RecruitingNCT02484248KetotifenUpdated Jan 9, 2026

Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia

A Phase 3 interventional study of Ketotifen and Placebo in Functional Dyspepsia, sponsored by Craig A. Friesen, MD. Recruiting at 1 site in United States. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Craig A. Friesen, MD · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2015; still recruiting 11 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
8 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Eosinophilia with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Eosinophilia · United States.

Planned enrollment
11th of 22
40 · median 37
Started
2015
the only one that year
Phase 3
9 of 31
1 open now
Registered
16th of 31
by date
Lead sponsor
1 of 31
Craig A. Friesen, MD

Among the 31 studies in Eosinophilia with a site in United States, this one is the 11th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2015, is one of 9 in phase 3, and was the 16th registered.

Eosinophilia

52 studies on the registry are indexed under Eosinophilia; 9 are open to participants now.

Browse Eosinophilia studies →

Open to participants now

5 of the 31 studies in Eosinophilia with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Eosinophilia studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 8 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Eosinophilia with a site in United States, or all of them as a file.
02

Study summary

Acid reduction remains the most common treatment prescribed empirically by pediatric gastroenterologists for children with functional dyspepsia (FD). When acid reduction therapy fails to provide patients with a therapeutic effect, ketotifen and cromolyn, mast cell stabilizers, represent an attractive potential therapy given data implicating mast cells in the generation of dyspeptic symptoms. Although there have been no adult or pediatric studies on the use of mast cell stabilizers in patients with FD, benefit has been demonstrated in adults with IBS and children with eosinophilic gastroenteritis. Additionally, previous studies show mucosal eosinophilia is highly correlated with functional dyspepsia. Our usual current treatment pathway for functional dyspepsia in association with duodenal mucosal eosinophilia is as follows: acid-reducing medication/montelukast → addition of H1 antagonist → addition of budesonide → addition of oral cromolyn. If ketotifen is effective, it offers the advantage of being able to replace both the H1 antagonist and the oral cromolyn at a substantially reduced cost (approximately 10% of the cost of cromolyn alone). This study aims to introduce ketotifen earlier in the treatment pathway to examine its efficacy on children with functional dyspepsia in association with duodenal eosinophilia.

Read the detailed description

This study is a double-blind, placebo-controlled, cross-over trial of ketotifen in children ages 8 through 17 inclusive that have a diagnosis of functional dyspepsia and have had continued abdominal pain despite acid reduction therapy in combination with montelukast. The primary aim is to assess the symptomatic response to ketotifen as compared to placebo in children with functional dyspepsia in association with duodenal eosinophilia who have previously had worsening, no clinical change, or only a partial response to acid-reduction therapy in combination with montelukast.

The study lasts 147 days for subjects responsive to ketotifen and 63 days for those who are not. For those who respond to ketotifen, there are 4 clinic visits and 3 phone interviews. Clinic visits include a physical, blood draws, questionnaires, review of medical history and medications; phone interviews involve answering a few questions. For those who do not respond to ketotifen, there are 3 clinic and 2 phone visits. Subjects who enroll in the study are randomly assigned to Group A or Group B. The subject, subject\'s parents, and study staff will not know to which group the subject is assigned. Group A will be given a placebo, an inactive pill with no medication in it, for days 1-28, and switched to ketotifen for days 36-63. Group B will be given ketotifen for days 1-28 and switched to placebo for days 36-63. The group assignment will be unblinded at day 63, at which point initial ketotifen responders will undergo an open-label twelve week trial of ketotifen to assess sustainability.

Secondary aims include: 1) assessing the impact of ketotifen as compared to placebo on quality of life; 2) assessing the sustainability of response to ketotifen in initial responders, and 3) assessing the pharmacokinetics of ketotifen in this patient population.

03

Conditions studied

  • Functional Dyspepsia

Browse trials for

Keywords

  • pediatric
  • eosinophilia
  • duodenal
  • ketotifen
  • functional dyspepsia
04

Who can participate

Ages eligible
8 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between the ages of 8 and 17 years, inclusive
  2. abdominal pain of at least 8 weeks duration and fulfilling symptom-based criteria for functional dyspepsia(5);
  3. previous endoscopy with demonstrating >20 eosinophils/high powered field on duodenal mucosal biopsies;
  4. previous treatment with acid-reduction therapy and montelukast with a level 3 (as defined below)or lesser response;
  5. evidence of written parental permission (consent) and subject assent;
  6. Negative pregnancy screening for females of child bearing potential.

Exclusion criteria

Exclusion Criteria:

  1. previous treatment with ketotifen;
  2. treatment with oral or oral cromolyn sodium in the 6 months prior to enrollment;
  3. any prior history of diabetes mellitus, cancer, chronic cardiac disease, respiratory disease, or renal disease requiring routine medical care;
  4. Pregnant/planning to become pregnant;
  5. Post-menarche females unwilling to use highly-efficacious to prevent pregnancy;
  6. Epilepsy or history of seizures;
  7. Liver disease or elevation of liver enzymes;
  8. Use of oral hypoglycemic medications, antipsychotics, benzodiazepines, tricyclic antidepressants, barbiturates, or opioids;
  9. Allergy to ketotifen or other products in capsule
  10. Refusal of Urine pregnancy test in post-menarchal females.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    cross-over of Ketotifen

    Patients will begin the active ketotifen treatment first and cross over to placebo.

    Drug: Ketotifen

  • Placebo comparator
    cross-over of Placebo

    Patients will begin the placebo treatment first and cross over to the active ketotifen.

    Drug: Placebo

Interventions

  • Ketotifen is an anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.

  • DrugPlacebo

    The placebo tablet looks identical to the ketotifen tablet, but does not contain ketotifen.

06

What researchers measure

Primary outcomes

  1. Complete Physical

    The study physician will check all systems and ask questions about pain and symptoms. This is a comprehensive system check to ensure safety. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  2. Blood pressure

    A trained professional will measure blood pressure to ensure value is within normal range and ensure safety of patient. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  3. Liver Functioning Test (a test ran from a blood sample to check a patients liver functioning)

    A blood sample is collected and tested by a certified laboratory for liver function. This will be completed and verified to be within normal ranges by the study physician to ensure patient safety. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  4. State-Trait Inventory for Cognitive and Somatic Anxiety - Child Version

    Anxiety score testing assessed with questionnaires. Anxiety scores are correlated with pain. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  5. Pediatric Quality of Life Inventory

    Quality of life survey for pediatrics to ensures maintenance of quality of life throughout study. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  6. Heart Rate

    A trained professional will measure heart rate to ensure value is within normal range and patient safety. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  7. Respiratory Rate

    A trained professional will measure respiratory rate to ensure value is within normal range and patient safety. Change is assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

Secondary outcomes

  1. Pharmacokinetic Sampling (Area under the plasma concentration versus time curve - AUC)

    Pharmacokinetic sampling allows for evaluation of the entire process of the drug breakdown by the body and ensures long term efficacy and safety. Change is being assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

  2. Pharmacokinetics Sampling (Peak Plasma Concentration - Cmax)

    Pharmacokinetic sampling allows for evaluation of the entire process of the drug breakdown by the body and ensures long term efficacy and safety. Change is being assessed from each time period.

    Time frame: day 0, day 28, day 63, and day 147

07

Study locations

1 of 1 sites recruiting
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Amber Bagherian, MS · Contactabagherian@cmh.edu · 816-234-3066
    • Craig A Friesen, MD · Principal investigator
    • Jennifer Colombo, MD · Sub investigator
    • Jennifer V Schurman, PhD · Sub investigator
    • Amanda D Deacy, PhD · Sub investigator
    • Susan Abdel-Rahman, PharmD · Sub investigator
08

References and documents

Publications

  • McFadyen ML, Miller R, Ludden TM. Ketotifen pharmacokinetics in children with atopic perennial asthma. Eur J Clin Pharmacol. 1997;52(5):383-6. doi: 10.1007/s002280050305. PubMed 9272408 ↗
  • Klooker TK, Braak B, Koopman KE, Welting O, Wouters MM, van der Heide S, Schemann M, Bischoff SC, van den Wijngaard RM, Boeckxstaens GE. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut. 2010 Sep;59(9):1213-21. doi: 10.1136/gut.2010.213108. Epub 2010 Jul 21. PubMed 20650926 ↗
  • Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c. PubMed 20479684 ↗
  • Hall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9. doi: 10.1053/s1542-3565(03)00184-8. PubMed 15017654 ↗
  • Friesen CA, Lin Z, Singh M, Singh V, Schurman JV, Burchell N, Cocjin JT, McCallum RW. Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008 Oct;53(10):2634-40. doi: 10.1007/s10620-008-0207-0. Epub 2008 Mar 5. PubMed 18320315 ↗
  • Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009 May 11;9:32. doi: 10.1186/1471-230X-9-32. PubMed 19432972 ↗
  • Santos J, Saperas E, Nogueiras C, Mourelle M, Antolin M, Cadahia A, Malagelada JR. Release of mast cell mediators into the jejunum by cold pain stress in humans. Gastroenterology. 1998 Apr;114(4):640-8. doi: 10.1016/s0016-5085(98)70577-3. PubMed 9516384 ↗
  • Stefanini GF, Saggioro A, Alvisi V, Angelini G, Capurso L, di Lorenzo G, Dobrilla G, Dodero M, Galimberti M, Gasbarrini G, et al. Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol. 1995 Jun;30(6):535-41. doi: 10.3109/00365529509089786. PubMed 7569760 ↗
  • Chen X, Zhong D, Liu D, Wang Y, Han Y, Gu J. Determination of ketotifen and its conjugated metabolite in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom. 2003;17(22):2459-63. doi: 10.1002/rcm.1189. PubMed 14608613 ↗
  • Grahnen A, Lonnebo A, Beck O, Eckernas SA, Dahlstrom B, Lindstrom B. Pharmacokinetics of ketotifen after oral administration to healthy male subjects. Biopharm Drug Dispos. 1992 May;13(4):255-62. doi: 10.1002/bdd.2510130404. PubMed 1600111 ↗
  • Friesen CS, Shakhnovich V, Toren P, Retke B, Schurman J, Colombo J, Deacy A, Friesen CA, Abdel-Rahman S. A Pilot Study of Ketotifen in Patients Aged 8-17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia. Paediatr Drugs. 2024 Jul;26(4):451-457. doi: 10.1007/s40272-024-00628-8. Epub 2024 May 21. PubMed 38771467 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2015 (actual). Primary completion is estimated for Apr 2027, 140 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2015
First posted
Jun 29, 2015
StartActual
Aug 2015
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02484248
Lead sponsor
Craig A. Friesen, MD
Responsible party
Craig A. Friesen, MD (Division Chief Gastroenterologist, Children's Mercy Hospital Kansas City) — Sponsor-investigator
First posted
Jun 29, 2015
Start date
Aug 2015
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Craig A Friesen, M.D.
Contact
cfriesen@cmh.edu
816-234-3066
Amber Bagherian, MS
Contact
abagherian@cmh.edu
816-234-3066
Craig A Friesen, MD
principal investigator · Children's Mercy Hospital Kansas City

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketotifen

Start the discussion